Pfizer Sutent Review: Partial Response Could Mean Clinical Benefit In RCC Setting
This article was originally published in The Pink Sheet Daily
Review documents for the targeted oncologic show FDA looking at the product’s approval for first-line renal cell carcinoma in the context of Bayer’s Nexavar approval for the same indication.
You may also be interested in...
Pfizer's Sutent received accelerated approval for first-line treatment of advanced renal cell carcinoma and full approval for treatment of refractory gastrointestinal stromal tumors.
FDA’s full approval of the oncologic indicates sorafenib for broad use by all patients with advanced renal cell carcinoma.
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.